Preclinical
Read moreParanta has developed PB01 to be administered intravenously during kidney transplantation for the prevention of delayed graft function. Prior to committing to a full clinical development program in patients undergoing kidney transplantation, Paranta will confirm preclinical proof of concept in a model of ischemia reperfusion injury. Results are anticipated by end Q1 2020.
Preclinical
Read morePB01 efficacy in renal DGF underpins the rationale to expand its use to other causes of AKI, such as: cardiovascular surgery, traumatic injury, clots and other causes of reduced blood flow to the kidneys; drug and toxin induced injury including chemotherapy; and sepsis.
Paranta Biosciences has progressed its recombinant human form of follistatin PB01
Paranta Biosciences is focused on the development and commercialization of PB01 to modulate the activin pathway for the treatment of inflammatory and fibrotic diseases. We welcome interest from parties looking to establish new alliances or collaboration opportunities that complement our research efforts and align with Paranta's corporate strategy.
We are open to collaborations that enable our partners to develop and commercialize Paranta's technologies worldwide, including out-licensing and R&D partnerships, and collaborations that maximize the potential of our pipeline, and our ability to deliver treatments to patients around the globe.
If you would like to discuss partnering with Paranta, please contact: contact@parantabio.com